Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwNHL 2015 | iwNHL 2015 roundtable: Molecular biology of T-cell lymphoma

Francesco d'Amore, Francine Foss, Laurence de Leval and Owen O'Connor • 3 Oct 2015
iwNHL 2015
Non-Hodgkin Lymphoma T-Cell Lymphoma

At the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2015 meeting, Francine M. Foss, MD, of the Yale University School of Medicine, New Haven, CT, chairs a discussion with Laurence de Leval, MD, PhD, of Institut universitaire de pathologie, Lausanne, Switzerland, Francesco d’Amore, MD, PhD of Aarhus University Hospital, Aarhus, Denmark, and Owen A. O’Connor, MD, PhD, Columbia University, New York, NY. Professor de Leval highlights recent discoveries in the molecular mechanisms of T-cell lymphoma development as well as the potential application of new biological markers for this patient population.

More from Francesco d'Amore

7:22
Managing T-cell lymphomas in light of the updated WHO classification
Francesco d'Amore • 27 Sep 2019
16:57
Clinical trials, pathologies and developments in personalized medicine
Francesco d'Amore et al. • 18 Sep 2017
iwNHL 2017: T-cell lymphomas, Hodgkin's lymphoma, immunotherapy and epigenetics
Francesco d'Amore et al. • 8 Sep 2017
6:49
Update of peripheral T-cell lymphoma treatment
Elaine Jaffe et al. • 5 Sep 2014

More from Francine Foss

Updates on the biology and treatment of T-cell lymphoma
Francine Foss et al. • 17 Oct 2023
1:38
Predicting tipifarnib response in T-cell NHL
Francine Foss • 11 Dec 2021
1:09
Addressing disparities in lymphoma treatment
Francine Foss • 11 Dec 2021
1:34
The future of valemetostat in PTCL
Francine Foss • 11 Dec 2021

More from Laurence de Leval

Updates on the biology and treatment of T-cell lymphoma
Francine Foss et al. • 17 Oct 2023
12:31
T-cell lymphomas: murine models, in-situ treatments & screening for HTLV1
David Weinstock et al. • 16 Sep 2019
16:57
Clinical trials, pathologies and developments in personalized medicine
Francesco d'Amore et al. • 18 Sep 2017
6:49
Update of peripheral T-cell lymphoma treatment
Elaine Jaffe et al. • 5 Sep 2014

More from Owen O'Connor

6:47
Immunoepigenetic platforms for PTCL treatment
Owen O'Connor • 2 Jul 2019
4:42
PTCL arising as a PTLD: the efficacy of pralatrexate
Owen O'Connor • 19 Jun 2019
9:20
The role of epigenetic modulators in the pathogenesis of lymphomas
Anas Younes et al. • 18 Sep 2017
iwNHL 2017: The future of lymphoma research and treatment
Catherine Bollard et al. • 8 Sep 2017

Related Videos

3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
1:48
Novel immunotherapy approaches in lymphoma: CAR-T cells, bispecifics & sequencing
Gloria Iacoboni • 15 Apr 2024
2:09
Using lineage tracing to define responding CAR T-cells in patients with LBCL
Zinaida Good • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals